NMTC

UB Community Development, a subsidiary of United Bancorporation of Alabama, Inc., Announces $4.4 Million in New Markets Tax Credit Funds to McNeely Plastic Products, Inc.

Retrieved on: 
Friday, September 8, 2023
PB, Plastic, Food, Mississippi State University, Rehabilitation, NMTC, Water, United Bank, Plasticity product, Renewable energy

United Bank provided a $17 million source loan while the project received additional NMTC allocations from PB Community Impact Fund, LLC and Cadence Community Capital, LLC.

Key Points: 
  • United Bank provided a $17 million source loan while the project received additional NMTC allocations from PB Community Impact Fund, LLC and Cadence Community Capital, LLC.
  • McNeely Plastic Products is a single source supplier to over 100 companies across a multitude of markets and industries.
  • The project will expand the existing facility by 30,000 square feet and add an additional 57,000-square-foot warehouse and distribution facility.
  • Originally founded in 1983 as a distributor of plastic packaging products, they invested in their own manufacturing facilities in 1996.

NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 6, 2023
NMTC, DSM-IV codes, EDEN, Patient, Conference, Nursing

EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual presentation at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Key Points: 
  • EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual presentation at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
  • A pre-recorded presentation by CFO Ron McClurg will be made available on demand to registered investors beginning Monday, September 11, 2023 at 7:00 a.m.
  • To register for the conference, please visit the conference website .
  • One-on-one meeting requests are available upon registration.

Novogradac Promotes Nine Managers to Principal Across Country

Retrieved on: 
Wednesday, September 6, 2023
Tax credit, Xavier University, Ohio State University, University of California, Davis, Housing, University, U.S. Department of Housing and Urban Development, Office of Inspector General, Oregon State University, Accounting, Office of Inspector General, U.S. Department of Health and Human Services, HUD, HTC, Sale, Brigham Young University, Certification, OZ, Walsh University, Publication, Juergen M. Geissinger, Investment, Community service, HTC Global Services, Growth, LIHTC, Carothers, University of Akron, Economics, Oregon Housing and Community Services Department, Property management, NMTC, St. Louis

SAN FRANCISCO, Sept. 6, 2023 /PRNewswire-PRWeb/ -- National accounting and consulting enterprise Novogradac elevated nine managers to principal Sept. 1–Nathan Berrett of the Walnut Creek, California, office; Christoper Carothers and Michael Wong of the San Francisco office; Morgan Debusk of the Portland, Oregon, office; Cody Geissinger and Douglas Sellers of the Dover, Ohio, office; Nick Gettings of the St. Louis office; and Logan O'Sicky and Marcos Velazquez of the Cleveland office.

Key Points: 
  • "My partners and I are proud to promote this group of dedicated managers," said Michael J. Novogradac, managing partner of Novogradac.
  • Carothers provides audit and consulting services to clients that include real estate developers, real estate investment companies, stakeholders in renewable energy and nonprofit organizations.
  • He also specializes in financial reporting for consolidations, business combinations, sale-leaseback transactions and investment company fair value reporting.
  • Before joining Novogradac, he worked at a major accounting firm as a senior audit manager specializing in private equity and venture capital financial reporting.

NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Mayo Clinic, Completeness, SG, DSM-IV codes, Brain, Research and development, NMTC, ATM, Patient, Administration, Clinical professor, EDEN, Evo, Research, FDA, R, Pharmaceutical industry

Product revenue was $630,000 in the fiscal third quarter 2023, compared to product revenue of $32,000 in the fiscal third quarter 2022.

Key Points: 
  • Product revenue was $630,000 in the fiscal third quarter 2023, compared to product revenue of $32,000 in the fiscal third quarter 2022.
  • Total operating expenses in the fiscal third quarter 2023 were $3.8 million, compared with $2.8 million in the same period of the prior fiscal year.
  • Research and Development (R&D) expense in the fiscal third quarter 2023 was $1.9 million compared with $1.2 million in the same period of fiscal 2022.
  • R&D expense in the first nine months of fiscal 2023 was $5.2 million compared with $3.5 million in the same period of fiscal 2022.

NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14

Retrieved on: 
Tuesday, August 8, 2023
NMTC, DSM-IV codes, EDEN, Patient, Conference, Pharmaceutical industry, Broadcasting

EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.

Key Points: 
  • EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.
  • Conference Call and Webcast Information:

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Tuesday, July 25, 2023
Benchmark, Exercise, Telephone, Stereoelectroencephalography, DSM-IV codes, Enterprise file synchronization and sharing, Sale, NMTC, Prospectus, Patient, Form, EDEN, FDA, EVO, Security (finance), Financial adviser

EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 5,250,000 shares of its common stock at a price of $1.00 per share.

Key Points: 
  • EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 5,250,000 shares of its common stock at a price of $1.00 per share.
  • All of the shares of common stock to be sold in the offering will be sold by the Company.
  • In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 787,500 shares of its common stock at the public offering price less the underwriting discount.
  • Kestrel Merchant Partners group at The Benchmark Company, LLC is responsible for sourcing and executing the offering.

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, July 24, 2023
Benchmark, Telephone, Stereoelectroencephalography, DSM-IV codes, Enterprise file synchronization and sharing, Sale, NMTC, Prospectus, Patient, Form, EDEN, FDA, EVO, Financial adviser

EDEN PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.

Key Points: 
  • EDEN PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.
  • All of the shares of common stock to be sold in the proposed offering will be sold by the Company.
  • In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Advantage Capital Invests $3.35 Million in Vibrant Corporation to Facilitate Expansion, Increase Production

Retrieved on: 
Tuesday, July 18, 2023
Other Professional Services, Finance, Other Transport, Professional Services, Air, Aerospace, Transport, Manufacturing, Electricity generation, Workforce, Boeing, Automotive industry, NDT, NMTC, Traction, Vibrant consonant, Project Y, Economic development, Airbus, Capital, Collins Aerospace, Airline, Renewable energy

Advantage Capital, a leading impact investing firm, today announced a $3.35 million investment in Vibrant Corporation, a non-destructive testing (NDT) technology company.

Key Points: 
  • Advantage Capital, a leading impact investing firm, today announced a $3.35 million investment in Vibrant Corporation, a non-destructive testing (NDT) technology company.
  • Advantage Capital led the round, with several pre-existing Vibrant shareholders also participating.
  • The company will leverage this funding to expand its workforce and increase production.
  • “We are pleased to have received this funding at this critical moment in our growth trajectory,” said Lem Hunter, Chief Executive Officer, Vibrant Corporation.

NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System 

Retrieved on: 
Monday, June 12, 2023
Stereoelectroencephalography, DSM-IV codes, Brain, Temperature, NMTC, Neurosurgery, Patient, EDEN, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Food, Software, Medical device

EDEN PRAIRIE, Minn., June 12, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery.

Key Points: 
  • If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery.
  • As the Company’s first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities.
  • The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation.
  • We also believe this system has applications beyond ablation of nervous tissue in the brain, offering a larger opportunity than we initially envisioned.

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

Retrieved on: 
Wednesday, May 17, 2023
Cleveland Clinic, Partnership, Surgeon, Stereoelectroencephalography, DSM-IV codes, Brain, ROSA, NMTC, Electrode, Neurosurgery, Patient, EDEN, Evo, Robotics, FDA, Medical device

EDEN PRAIRIE, Minn., May 17, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo® sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne’s Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.

Key Points: 
  • EDEN PRAIRIE, Minn., May 17, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo® sEEG electrode in robotic neurosurgery.
  • Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne’s Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet’s ROSA One® Brain , a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.
  • Dave Rosa, CEO of NeuroOne, commented, “This clinical case utilizing our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet.
  • In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.